News >

Quizartinib Data Move FLT3 Inhibition Forward in AML Paradigm

Gina Columbus @ginacolumbusonc
Published: Tuesday, Mar 19, 2019

FLT3 inhibition continues to be explored as a therapeutic option for patients with FLT3-mutant acute myeloid leukemia (AML), with quizartinib at the forefront following intriguing results of the phase III QuANTUM-R trial, experts discussed during an OncLive® Peer Exchange®.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x